Comprehensive Stock Comparison
Compare Ultragenyx Pharmaceutical Inc. (RARE) vs BridgeBio Pharma, Inc. (BBIO) Stock
Analyze side-by-side fundamentals, valuation, growth, and profitability to decide which stock is the better buy.
Selected Stocks
Add up to 10 tickers. Use presets or search to get started.
Quick Verdict
| Category | Winner | Why |
|---|---|---|
| Growth | BBIO | 126.3% revenue growth vs RARE's 29.0% |
| Quality / Margins | RARE | -91.9% net margin vs BBIO's -145.3% |
| Stability / Safety | RARE | Beta 0.95 vs BBIO's 1.04 |
| Dividends | Tie | Neither pays a meaningful dividend |
| Momentum (1Y) | BBIO | +90.5% vs RARE's -45.5% |
| Efficiency (ROA) | RARE | -48.7% ROA vs BBIO's -77.9% |
Who Each Stock Is For
Income & stability
Growth exposure
Long-term compounding (10Y)
Sleep-well-at-night portfolio
Defensive / Recession hedge
Business Model
What each company does and how it makes money
Ultragenyx Pharmaceutical is a biopharmaceutical company that develops and commercializes treatments for rare and ultra-rare genetic diseases. It generates revenue primarily from sales of its approved therapies—including Crysvita for X-linked hypophosphatemia, Mepsevii for Mucopolysaccharidosis VII, and Dojolvi for fatty acid oxidation disorders—supplemented by milestone payments from partnerships. The company's competitive advantage lies in its specialized focus on niche genetic disorders where it can establish orphan drug exclusivity and build deep expertise in complex disease biology.
BridgeBio Pharma is a biopharmaceutical company focused on discovering and developing precision medicines for genetic diseases. It generates revenue primarily through drug development partnerships and potential future product sales — though currently in pre-revenue stage with multiple programs in clinical trials. The company's key advantage is its efficient hub-and-spoke operating model that allows rapid development of targeted therapies for rare genetic conditions.
Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
Financial Metrics Comparison
Side-by-side fundamentals across 2 stocks. BestLagging
Financial Scorecard
BBIO leads in 1 of 6 categories (Total Returns). RARE leads in 1 (Analyst Outlook). 4 tied.
Financial Metrics (TTM)
RARE and BBIO operate at a comparable scale, with $631M and $502M in trailing revenue. RARE is the more profitable business, keeping -91.9% of every revenue dollar as net income compared to BBIO's -145.3%. On growth, BBIO holds the edge at +25.2% YoY revenue growth, suggesting stronger near-term business momentum.
| Metric | RAREUltragenyx Pharma… | BBIOBridgeBio Pharma,… |
|---|---|---|
| RevenueTrailing 12 months | $631M | $502M |
| EBITDAEarnings before interest/tax | -$509M | -$560M |
| Net IncomeAfter-tax profit | -$580M | -$729M |
| Free Cash FlowCash after capex | -$451M | -$458M |
| Gross MarginGross profit ÷ Revenue | +84.7% | +94.4% |
| Operating MarginEBIT ÷ Revenue | -86.3% | -113.3% |
| Net MarginNet income ÷ Revenue | -91.9% | -145.3% |
| FCF MarginFCF ÷ Revenue | -71.6% | -91.1% |
| Rev. Growth (YoY)Latest quarter vs prior year | +14.7% | +25.2% |
| EPS Growth (YoY)Latest quarter vs prior year | -29.3% | +28.6% |
Valuation Metrics
| Metric | RAREUltragenyx Pharma… | BBIOBridgeBio Pharma,… |
|---|---|---|
| Market CapShares × price | $2.3B | $12.9B |
| Enterprise ValueMkt cap + debt − cash | $2.1B | $12.4B |
| Trailing P/EPrice ÷ TTM EPS | -3.72x | -17.54x |
| Forward P/EPrice ÷ next-FY EPS est. | — | — |
| PEG RatioP/E ÷ EPS growth rate | — | — |
| EV / EBITDAEnterprise value multiple | — | — |
| Price / SalesMarket cap ÷ Revenue | 4.03x | 25.79x |
| Price / BookPrice ÷ Book value/share | 8.07x | — |
| Price / FCFMarket cap ÷ FCF | — | — |
Profitability & Efficiency
On the Piotroski fundamental quality scale (0–9), RARE scores 4/9 vs BBIO's 3/9, reflecting mixed financial health.
| Metric | RAREUltragenyx Pharma… | BBIOBridgeBio Pharma,… |
|---|---|---|
| ROE (TTM)Return on equity | -35.9% | — |
| ROA (TTM)Return on assets | -48.7% | -77.9% |
| ROICReturn on invested capital | -3.4% | — |
| ROCEReturn on capital employed | -45.2% | -80.6% |
| Piotroski ScoreFundamental quality 0–9 | 4 | 3 |
| Debt / EquityFinancial leverage | 0.15x | — |
| Net DebtTotal debt minus cash | -$133M | -$560M |
| Cash & Equiv.Liquid assets | $174M | $570M |
| Total DebtShort + long-term debt | $40M | $10M |
| Interest CoverageEBIT ÷ Interest expense | -8.93x | -6.10x |
Total Returns (with DRIP)
A $10,000 investment in BBIO five years ago would be worth $9,245 today (with dividends reinvested), compared to $1,642 for RARE. Over the past 12 months, BBIO leads with a +90.5% total return vs RARE's -45.5%. The 3-year compound annual growth rate (CAGR) favors BBIO at 79.9% vs RARE's -19.3% — a key indicator of consistent wealth creation.
| Metric | RAREUltragenyx Pharma… | BBIOBridgeBio Pharma,… |
|---|---|---|
| YTD ReturnYear-to-date | -0.9% | -15.0% |
| 1-Year ReturnPast 12 months | -45.5% | +90.5% |
| 3-Year ReturnCumulative with dividends | -47.4% | +482.1% |
| 5-Year ReturnCumulative with dividends | -83.6% | -7.6% |
| 10-Year ReturnCumulative with dividends | -61.6% | +141.3% |
| CAGR (3Y)Annualised 3-year return | -19.3% | +79.9% |
Risk & Volatility
RARE is the less volatile stock with a 0.95 beta — it tends to amplify market swings less than BBIO's 1.04 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. BBIO currently trades 78.3% from its 52-week high vs RARE's 54.1% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | RAREUltragenyx Pharma… | BBIOBridgeBio Pharma,… |
|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 0.95x | 1.04x |
| 52-Week HighHighest price in past year | $43.22 | $84.94 |
| 52-Week LowLowest price in past year | $18.41 | $28.33 |
| % of 52W HighCurrent price vs 52-week peak | +54.1% | +78.3% |
| RSI (14)Momentum oscillator 0–100 | 47.0 | 39.0 |
| Avg Volume (50D)Average daily shares traded | 2.8M | 2.5M |
Analyst Outlook
Wall Street rates RARE as "Buy" and BBIO as "Buy". Consensus price targets imply 108.6% upside for RARE (target: $49) vs 48.8% for BBIO (target: $99).
| Metric | RAREUltragenyx Pharma… | BBIOBridgeBio Pharma,… |
|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Buy | Buy |
| Price TargetConsensus 12-month target | $48.78 | $98.92 |
| # AnalystsCovering analysts | 33 | 26 |
| Dividend YieldAnnual dividend ÷ price | — | — |
| Dividend StreakConsecutive years of raises | 1 | 0 |
| Dividend / ShareAnnual DPS | — | — |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | +0.4% |
Historical Charts
Charts are rendered on first load. Hover for details.
Chart 1Total Return — 5 Years (Rebased to 100)
| Stock | Feb 20 | Feb 26 | Change |
|---|---|---|---|
| Ultragenyx Pharmace… (RARE) | 100 | 44.15 | -55.8% |
| BridgeBio Pharma, I… (BBIO) | 100 | 245.42 | +145.4% |
BridgeBio Pharma, I… (BBIO) returned -8% over 5 years vs Ultragenyx Pharmace… (RARE)'s -84%.
Chart 2Revenue Growth — 10 Years
| Stock | 2016 | 2025 | Change |
|---|---|---|---|
| Ultragenyx Pharmace… (RARE) | $133000.00 | $560M | +421125.6% |
| BridgeBio Pharma, I… (BBIO) | $0.00 | $502M | — |
Chart 3Net Margin Trend — 10 Years
| Stock | 2016 | 2025 | Change |
|---|---|---|---|
| Ultragenyx Pharmace… (RARE) | -1848.7% | -101.6% | +94.5% |
| BridgeBio Pharma, I… (BBIO) | -6.4% | -145.3% | -2162.2% |
Chart 4EPS Growth — 10 Years
| Stock | 2016 | 2025 | Change |
|---|---|---|---|
| Ultragenyx Pharmace… (RARE) | -6.21 | -6.29 | -1.3% |
| BridgeBio Pharma, I… (BBIO) | -0.33 | -3.79 | -1048.5% |
Chart 5Free Cash Flow — 5 Years
Ultragenyx Pharmaceutical Inc. generated $-422M FCF in 2024 (-2% vs 2021). BridgeBio Pharma, Inc. generated $-447M FCF in 2025 (+18% vs 2021).
RARE vs BBIO: Frequently Asked Questions
7 questions · data-driven answers · updated daily
01Is RARE or BBIO a better buy right now?
Analysts rate Ultragenyx Pharmaceutical Inc. (RARE) a "Buy" — based on 33 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which is the better long-term investment — RARE or BBIO?
Over the past 5 years, BridgeBio Pharma, Inc. (BBIO) delivered a total return of -7.6%, compared to -83.6% for Ultragenyx Pharmaceutical Inc. (RARE). A $10,000 investment in BBIO five years ago would be worth approximately $9K today (assuming dividends reinvested). Over 10 years, the gap is even starker: BBIO returned +141.3% versus RARE's -61.6%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
03Which is safer — RARE or BBIO?
By beta (market sensitivity over 5 years), Ultragenyx Pharmaceutical Inc. (RARE) is the lower-risk stock at 0.95β versus BridgeBio Pharma, Inc.'s 1.04β — meaning BBIO is approximately 9% more volatile than RARE relative to the S&P 500.
04Which has better profit margins — RARE or BBIO?
Ultragenyx Pharmaceutical Inc. (RARE) is the more profitable company, earning -101.6% net margin versus -145.3% for BridgeBio Pharma, Inc. — meaning it keeps -101.6% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: RARE leads at -95.7% versus -113.3% for BBIO. At the gross margin level — before operating expenses — BBIO leads at 94.4%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
05Which pays a better dividend — RARE or BBIO?
None of the stocks in this comparison currently pay a material dividend. All are effectively zero-yield and should be held for capital appreciation rather than income.
06Is RARE or BBIO better for a retirement portfolio?
For long-horizon retirement investors, BridgeBio Pharma, Inc. (BBIO) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 1.04), +141.3% 10Y return). Both have compounded well over 10 years (BBIO: +141.3%, RARE: -61.6%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
07What are the main differences between RARE and BBIO?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that beat both.